13D Filing: James E. Flynn and Homology Medicines Inc (FIXX)

Page 9 of 20

Page 9 of 20 – SEC Filing

SCHEDULE 13D

CUSIP No.  438083107 Page 9 of 18 Pages
1

NAME OF REPORTING PERSONS

James E. Flynn

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐

(b) ☒

3

SEC USE ONLY

4

SOURCE OF FUNDS

AF

5

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)

6

CITIZENSHIP OR PLACE OF ORGANIZATION

United States of America

 

 

 NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

5,227,035 (5)

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

5,227,035 (5)

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

5,227,035 (5)

12

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES*

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

13.96%

14

TYPE OF REPORTING PERSON

IN

(5) Comprised of 2,613,517 shares held by Deerfield Private
Design Fund III, L.P., 625,000 shares held by Deerfield Partners, L.P. and 1,988,518 shares held by Deerfield Healthcare Innovations
Fund, L.P.

Follow Q32 Bio Inc. (NASDAQ:QTTB)

Page 9 of 20